1. Home
  2. FOF vs FBRX Comparison

FOF vs FBRX Comparison

Compare FOF & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Closed-End Opportunity Fund Inc.

FOF

Cohen & Steers Closed-End Opportunity Fund Inc.

HOLD

Current Price

$13.61

Market Cap

371.4M

Sector

Finance

ML Signal

HOLD

Logo Forte Biosciences Inc.

FBRX

Forte Biosciences Inc.

HOLD

Current Price

$32.42

Market Cap

487.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOF
FBRX
Founded
2006
N/A
Country
United States
United States
Employees
N/A
19
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
371.4M
487.2M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
FOF
FBRX
Price
$13.61
$32.42
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$67.00
AVG Volume (30 Days)
76.3K
375.3K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
9.07%
N/A
EPS Growth
N/A
61.30
EPS
N/A
N/A
Revenue
N/A
$36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.14
$4.91
52 Week High
$15.04
$35.80

Technical Indicators

Market Signals
Indicator
FOF
FBRX
Relative Strength Index (RSI) 57.48 61.85
Support Level $12.75 $26.67
Resistance Level $14.50 $35.62
Average True Range (ATR) 0.25 3.65
MACD 0.12 0.94
Stochastic Oscillator 94.73 75.41

Price Performance

Historical Comparison
FOF
FBRX

About FOF Cohen & Steers Closed-End Opportunity Fund Inc.

Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. The Fund's investment objective is to achieve total return, consisting of high current income and potential capital appreciation.

About FBRX Forte Biosciences Inc.

Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.

Share on Social Networks: